Oticon Medical General Manager after US FDA approval: It's a competitive situation

Demant's bone-anchored division Oticon Medical will be put to the test when establishing itself on the US market for cochlear implants following the FDA approval last week. Competing companies are far ahead, and the Danish firm still has gaps to close in its product range, according to General Manager Jes Olsen.

On Thursday last week, Demant's bone-anchored division was delighted to announce that the US Food and Drug Administration (FDA) has given the necessary authorization for the Danish hearing company to sell and market its cochlear implant system Neuro 2 on what is unconditionally the largest market in the world.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading